Mana.bio utilizes machine learning and nanotechnology to develop lipid nanoparticle drug delivery systems for gene therapies, including DNA and RNA-based therapeutics and vaccines. The startup addresses the inefficiencies in current drug delivery methods, aiming to enhance the precision and effectiveness of therapeutic applications.
Funding
$24.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug delivery systems for gene therapies, including DNA and RNA-based therapeutics and vaccines, often suffer from inefficiencies that limit the precision and effectiveness of therapeutic applications. These limitations can hinder the potential of advanced gene therapies to treat a wide range of diseases.
Solution
Mana.bio develops lipid nanoparticle (LNP) drug delivery systems for gene therapies using a combination of machine learning and nanotechnology. Their platform aims to enhance the precision and effectiveness of delivering DNA and RNA-based therapeutics and vaccines. By integrating machine learning algorithms with nanotechnology, Mana.bio identifies optimal LNP formulations to improve drug delivery outcomes. This approach seeks to overcome the limitations of existing drug delivery methods, potentially expanding the therapeutic applications of gene therapies.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in the development and delivery of gene therapies.
Features
- Machine learning-driven identification of optimal lipid nanoparticle formulations.
- Nanotechnology-based design of drug delivery systems.
- Focus on gene therapies, including DNA and RNA-based therapeutics and vaccines.